



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:

Sheryl Seapy, Pure Communications Inc.
949-608-0841

XDx Announces Blue Shield of California Considers AlloMap® Medically Necessary for Monitoring Heart Transplant Rejection

Continued Adoption by Leading Insurers Further Validates AlloMap's Clinical Utility

BRISBANE, CA, August 17, 2011 – XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive gene expression tests to monitor immune-mediated conditions, today announced that Blue Shield of California considers AlloMap® “medically necessary” for monitoring heart transplant rejection more than one year post-transplant. By assuring coverage of AlloMap for its eligible patients, Blue Shield of California recognizes the clinical utility of this non-invasive method of determining the risk of rejection in stable heart transplant recipients.

“The rapid adoption of AlloMap by leading institutions and the favorable recommendation of AlloMap in the 2010 International Society of Heart and Lung Transplant (ISHLT) guidelines for the care of heart transplant recipients have established AlloMap as the new standard of care for stable heart transplant patients,” said Pierre Cassigneul, president and CEO of XDx. “We are very pleased with Blue Shield of California’s favorable coverage decision, providing us with the opportunity to impact the quality of life for stable patients by reducing the number of invasive biopsies performed post-transplantation.”

In the United States, there are about 2,100 heart transplants performed each year and approximately 20,000 living heart transplant recipients. Advances in immunosuppression have improved the survival rates following cardiac transplantation, but the risk of acute cellular rejection persists for several years and is associated with graft loss. Heart transplant recipients may undergo endomyocardial biopsies for years after transplantation. Invasive biopsy procedures may be associated with discomfort, inconvenience and infrequent but potentially serious risks of

complications. AlloMap is a simple, non-invasive blood test that aids physicians in evaluating the risk for heart transplant rejection.

About AlloMap® Molecular Expression Technology

AlloMap Molecular Expression Testing is a non-invasive gene expression test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the XDx CLIA-certified laboratory and has been commercially available since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in April 2011. Use of AlloMap is also included in the International Society of Heart and Lung Transplant (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. Approximately 65% of the United States heart transplant population is covered for AlloMap.

About XDx

XDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMap Molecular Expression Testing, an FDA-cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. Some of the AlloMap technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx's non-invasive technology offers the potential to decrease healthcare costs and improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases. For more information, please visit www.xdx.com.

###